MoonLake Immunotherapeutics 4

CEO Jorge Santos da Silva sold 102,225 MoonLake Immunotherapeutics (MLTX) Class A shares in open-market transactions totaling roughly $2.05 million.

On July 9 and 10, 2026, MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold a total of 102,225 Class A ordinary shares under a pre-arranged Rule 10b5-1 trading plan at weighted average prices of approximately $20.01 and $20.02 per share, for aggregate proceeds of about $2.05 million. These open-market sales, executed in multiple trades within narrow price ranges around $20, reduced his direct holdings from 2,843,182 to 2,774,893 Class A ordinary shares, which remain a substantial ownership position. The Form 4 notes that detailed trade-by-trade pricing information is available upon request from the SEC, the issuer, or a security holder.

Filing Facts

CIK

1821586

Ticker

MLTX

Form

4

Source Type

fda

Accession

0001213900-26-077564

Alert Tier

7